Tetracore
Private Company
Total funding raised: $34.5M
Overview
Tetracore is a long-established, commercial-stage diagnostics company specializing in assays and instruments for infectious diseases and biodefense. Its product portfolio spans lateral flow assays (LFA), real-time PCR systems, and multiplex immunoassays, targeting both human and veterinary pathogens. The company operates primarily as a B2B supplier to government, public health, and veterinary laboratories, focusing on providing actionable, on-site diagnostic solutions. Its dual focus on biothreat agents and endemic infectious diseases positions it in stable, mission-critical markets.
Technology Platform
Multi-modal diagnostics platform encompassing lateral flow immunoassays (LFA) with portable readers, real-time PCR systems (T-COR 8 thermocycler and assays), and multiplex bead-based immunoassays (FlexImmArray for Luminex systems).
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Tetracore competes with large diversified diagnostics companies (e.g., Abbott, bioMérieux, Qiagen) in infectious disease testing, and with specialized biodefense contractors (e.g., Battelle, MRIGlobal) and other niche assay developers. Its differentiation lies in its dedicated focus on biothreats and field-deployable integrated systems.